Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms

Published:2016-01 Issue:1 Volume:7 Page:e2063-e2063
ISSN:2041-4889
Container-title:Cell Death & Disease
language:en
Short-container-title:Cell Death Dis

Author:

Wang L,Li H,Ren Y,Zou S,Fang W,Jiang X,Jia L,Li M,Liu X,Yuan X,Chen G,Yang J,Wu C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology

Link

http://www.nature.com/articles/cddis2015328.pdf

Reference36 articles.

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87–108.

2. Reck M, Heigener DF, Mok T, Soria JC, Rabe KF . Management of non-small-cell lung cancer: recent developments. Lancet 2013; 382: 709–719.

3. Evans T . Chemotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2005; 26: 304–313.

4. Simon GR . Nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update. Clin Lung Cancer 2014; 15: 391–397.

5. Socinski MA . Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Curr Oncol 2014; 21: e691–e703.

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blocking lncRNA HCG18 re-sensitizes Taxol resistant lung cancer cells to Taxol through modulating the miR-34a-5p/HDAC1 axis;Journal of Chemotherapy;2024-05-06

2. Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator;Medical Oncology;2024-03-05

3. A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids;npj Precision Oncology;2024-02-27

4. EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis;Cell Reports;2024-02

5. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors;Frontiers in Immunology;2023-11-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3